Fleury Raphael, Bertail Théophile, Bensalah Karim, Bernhard Jean-Christophe, Audenet Francois, Waeckel Thibaut, Parier Bastien, Champy Cécile, Olivier Jonathan, Doumerc Nicolas, Tricard Thibault, Branger Nicolas, Bruyere Franck, Neuville Paul, Surlemont Louis, Alexandre Long Jean, Fontenil Alexis, Vallee Maxime, Roupret Morgan, Boissier Romain, Jacques Patard Jean, Durand Mathieu, Ouzaid Idir, Rouget Benjamin, Durand Xavier, Joncour Charlotte, Belas Olivier, Denise Gomez Florie, Bigot Pierre, Khene Zine-Eddine
Department of Urology, Centre Hospitalier Universitaire de Rennes, Rennes, France.
LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.
Eur Urol Open Sci. 2024 Mar 8;62:123-130. doi: 10.1016/j.euros.2024.02.015. eCollection 2024 Apr.
There is no definitive evidence of the prognosis impact of histological variants (HVs) in patients who undergo surgical resection of a nonmetastatic renal cell carcinoma (nm-RCC) with venous tumor thrombus (TT).
To investigate the impact of HVs on the prognosis of patients with nm-RCC with TT after radical surgery.
Patients who underwent radical nephrectomy with the removal of the venous TT for an nm-RCC were included in a retrospective study.
Three groups were identified: clear cell (ccRCC), papillary (pRCC), and chromophobe (chRCC) RCC. The primary outcome measures (disease-free and overall survival [OS]) were assessed using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate Cox proportional hazard models were used to study the impact of HVs on survival.
A total of 873 patients were included. The histological subtypes were distributed as follows: ccRCC in 780 cases, pRCC in 58 cases, and chRCC in 35 cases. At the time of data analysis, 612 patients were recurrence free and 228 had died. A survival analysis revealed significant differences in both OS and recurrence-free survival across histological subtypes, with the poorest outcomes observed in pRCC patients ( < 0.05). In a multivariable analysis, pRCC was independently associated with worse disease-free survival and OS (hazard ratio [HR]: 1.71; = 0.01 and HR: 1.24; = 0.04), while chRCC was associated with more favorable outcomes than ccRCC (HR: 0.05; < 0.001 and HR: 0.02; < 0.001). A limitation of the study is its retrospective nature.
In this multicentric series, HVs appeared to impact the medium-term oncological prognosis of kidney cancer with TT.
This study investigated the differences in oncological outcomes among histological variants (clear cell, papillary, and chromophobe) in a cohort of nonmetastatic renal cell carcinoma patients with venous tumor thrombus extension. We observed that these histological variants within this specific subgroup exhibit distinct outcomes, with papillary renal cell carcinoma being associated with the worst prognosis.
对于接受手术切除伴有静脉瘤栓(TT)的非转移性肾细胞癌(nm-RCC)患者,组织学亚型(HV)对预后影响尚无确凿证据。
探讨HV对根治性手术后nm-RCC伴TT患者预后的影响。
设计、背景与参与者:纳入接受根治性肾切除术并切除nm-RCC静脉TT的患者进行回顾性研究。
分为三组:透明细胞(ccRCC)、乳头状(pRCC)和嫌色(chRCC)肾细胞癌。主要结局指标(无病生存期和总生存期[OS])采用Kaplan-Meier法评估,并使用对数秩检验进行比较。采用单因素和多因素Cox比例风险模型研究HV对生存的影响。
共纳入873例患者。组织学亚型分布如下:ccRCC 780例,pRCC 58例,chRCC 35例。在数据分析时,612例患者无复发,228例死亡。生存分析显示,不同组织学亚型的OS和无复发生存期存在显著差异,pRCC患者预后最差(P<0.05)。多变量分析中,pRCC与较差的无病生存期和OS独立相关(风险比[HR]:1.